Martin P. Sebastian

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: June 19, 2026

Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

Journal: Cancers

Published: May 21, 2026

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: April 17, 2026

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: December 12, 2025

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 04, 2025

Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.

Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: November 21, 2025

Preoperative Immunotherapy in Oncology.

Preoperative Immunotherapy in Oncology.

Journal: Deutsches Arzteblatt international

Published: November 20, 2025

Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany.

Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany.

Journal: Therapeutic advances in medical oncology

Published: November 07, 2025

Response to Trastuzumab Deruxtecan in a Patient With EGFR-Mutated NSCLC and Transformation to SCLC Harboring HER2 Amplification: A Case Report.

Response to Trastuzumab Deruxtecan in a Patient With EGFR-Mutated NSCLC and Transformation to SCLC Harboring HER2 Amplification: A Case Report.

Journal: JTO clinical and research reports

Published: October 29, 2025

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 08, 2025

Anaesthesia and analgesia for total knee arthroplasty.

Anaesthesia and analgesia for total knee arthroplasty.

Journal: BJA education

Published: September 28, 2025

Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA.

Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 27, 2025

Showing 1-12 of 104

Last Updated: 09/26/2026